Vascular endothelial dysfunction in cirrhosis

Slides:



Advertisements
Similar presentations
CELLULAR BIOLOGY OF BLOOD VESSELS The biology of the vascular wall is essential to understanding the pathophysiology of atherosclerosis, vasospasm, and.
Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Role for peroxynitrite in the inhibition of prostacyclin.
Polymorphisms in endothelial nitric oxide synthase and atherogenesis
From: Nitric Oxide: A Physiologic Messenger
Cirrhotic cardiomyopathy
Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.
Figure 1 Pre-eclampsia prevents VEGF signalling in endothelial cells
Volume 4, Issue 3, Pages (June 2006)
Signal trasduction via cAMP
Volume 53, Issue 3, Pages (September 2010)
Carmen Peralta, Mónica B. Jiménez-Castro, Jordi Gracia-Sancho 
Manuel Mas  European Urology Supplements 
Reactive oxygen species in the normal and acutely injured liver
Prevention of ischemia-reperfusion injury in cardiac surgery: Therapeutic strategies targeting signaling pathways  Kay Maeda, MD, PhD, Marc Ruel, MD,
Recent insights on the mechanisms of liver preconditioning
Gianluca Tell, Carlo Vascotto, Claudio Tiribelli  Journal of Hepatology 
HFpEF, a Disease of the Vasculature: A Closer Look at the Other Half
Cirrhotic cardiomyopathy
Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model  Eric S. Weiss, MD,
Volume 151, Issue 2, Pages (February 2017)
Exercise and Endothelium
Hedgehog signaling in the liver
The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.
Physiology of the endothelium
Gene Therapy for Erectile Dysfunction: Fact or Fiction?
Daniel A. Langer, Vijay H. Shah  Journal of Hepatology 
Volume 56, Issue 3, Pages (March 2012)
Circulating microparticles from patients with valvular heart disease and cardiac surgery inhibit endothelium-dependent vasodilation  Li Fu, MD, Xiao-Xia.
Volume 151, Issue 2, Pages (February 2017)
Nat. Rev. Nephrol. doi: /nrneph
Inflammation and portal hypertension – The undiscovered country
Divya Gupta et al. JCHF 2013;1:
Signalling pathways in alcohol-induced liver inflammation
Evaluation of the microcirculation in vascular disease
Michael G. Katz, MD, PhD, Anthony S. Fargnoli, PhD, Andrew P
Muhammad Arshad, MD, Venkataramana Vijay, MD, Beverly C
Sinusoidal communication in liver fibrosis and regeneration
Carmen Peralta, Mónica B. Jiménez-Castro, Jordi Gracia-Sancho 
Yasuko Iwakiri, Vijay Shah, Don C. Rockey  Journal of Hepatology 
Hypoxia-inducible factor pathway and diseases of the vascular wall
The sources of oxidative stress in the vessel wall
Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.
Volume 66, Issue 1, Pages (January 2017)
The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.
Volume 81, Issue 12, Pages (June 2012)
Guo-Wei He, MD, DSc, David P. Taggart, FRCS 
Thomas Quaschning, Jan Galle, Christoph Wanner
Juan-Carlos García-Pagán, Jorge Gracia-Sancho, Jaume Bosch 
Margus Annuk, Mihkel Zilmer, Bengt Fellström
Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome  Nassrene Y. Elmadhun, MD, Antonio D.
Volume 132, Issue 2, Pages (February 2007)
Cyclooxygenase-2 in the kidney: good, BAD, or both?
Volume 70, Issue 10, Pages (November 2006)
Volume 86, Issue 2, Pages (August 2014)
Heme oxygenase: protective enzyme or portal hypertensive molecule?
Therapeutic strategies in inflammasome mediated diseases of the liver
Mary P. Kotlarczyk, PhD, Marie Billaud, PhD, Benjamin R
Preconditioning and cardiac surgery
Figure 2 Protective functions of HDL
Volume 81, Issue 8, Pages (April 2012)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease  Michal Pawlak,
Specific signal transduction mechanisms
Constantijn Franssen et al. JCHF 2016;4:
Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies  Ben M Tsai, MD, Meijing Wang, MD, Mark W Turrentine,
Mechanism of action for pulmonary arterial hypertension medications.
Biology of endothelin receptors in the collecting duct
Impaired Lung Function and Risk for Stroke
Spasm in Arterial Grafts in Coronary Artery Bypass Grafting Surgery
Christian Rask-Madsen, George L. King  Cell Metabolism 
Presentation transcript:

Vascular endothelial dysfunction in cirrhosis Yasuko Iwakiri, Roberto J. Groszmann  Journal of Hepatology  Volume 46, Issue 5, Pages 927-934 (May 2007) DOI: 10.1016/j.jhep.2007.02.006 Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Vasoactive molecules known to be involved in the regulation of vascular tone in cirrhosis. In the arterial splanchnic circulation (right panel), agonists such as adrenomedullin, vascular endothelial growth factor (VEGF) and tumor necrosis factor α (TNFα) or physical stimuli such as shear stress stimulate Akt, also known as protein kinase B, which directly phosphorylates and activates endothelial nitric oxide (NO) synthase (eNOS). eNOS is calcium (Ca2+)/calmodulin (CaM)-dependent and requires co-factors such as tetrahydrobiopterin (BH4) for its activity. Heat shock protein 90 (Hsp90) is one of positive regulators of eNOS. Like NO, carbon monoxide (CO) produced by hemeoxygenase-1 (HO-1) causes vasodilation by activating soluble guanylate cyclase (sGC) to generate cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells. Prostacyclin (PGI2) is synthesized by cyclooxygenase (COX) and elicits smooth muscle relaxation by stimulating adenylate cyclase (AC) and generation of cyclic adenosine monophosphate (cAMP) [16]. In the intrahepatic circulation (central panel), decreased NO and increased thromboxane A2 (TXA2) productions in SECs result in the net reduction of vasorelaxation in the intrahepatic circulation. Endothelin-1 (ET-1) has dual vasoactive effects, mediating vasoconstriction through binding to endothelin A (ETA) receptors located on HSCs and causing HSCs contraction [25]. Binding of ET-1 to ETB receptor (ETBR) mediates vasodilatation through Akt phosphorylation and eNOS phosphorylation via G-protein-coupled receptor signaling in normal liver [26]. In cirrhosis, G-protein-coupled receptor kinase-2 (GRK2), an inhibitor of G-protein-coupled receptor signaling, is up-regulated in SECs, leading to the impairment of Akt phosphorylation and a reduction in NO production [51]. Endotoxin [52,53] and reactive oxygen species (ROS) reduce NO production by increasing caveolin-1 (Cav-1) expression, increasing the interaction with eNOS, decreasing the association with ETBR and decreasing eNOS phosphorylation at Ser 1177 [46]. An increased production of COX-1-derived vasoconstrictor prostanoid TXA2 is also an example of endothelial dysfunction in cirrhosis [30]. Journal of Hepatology 2007 46, 927-934DOI: (10.1016/j.jhep.2007.02.006) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions